Mitoxantrone: Propensity for free radical formation and lipid peroxidation — implications for cardiotoxicity Raymond F. NovakEvan D. Kharasch OriginalPaper Pages: 95 - 99
Pharmacology of mitoxantrone: mode of action and pharmacokinetics David S. AlbertsYei Mei PengCindy Mackel OriginalPaper Pages: 101 - 107
The pharmacokinetics and metabolism of mitoxantrone in man Gerhard EhningerBarbara ProkschDavid L. Woodward OriginalPaper Pages: 109 - 116
Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update Robert S. BenjaminSant P. ChawlaFrankie Holmes OriginalPaper Pages: 117 - 121
Mitoxantrone: an overview of safety and toxicity Larry E. PosnerGary DukartKenneth Cartwright OriginalPaper Pages: 123 - 132
Mitoxantrone as a first-line treatment of advanced breast cancer Karl LandysStig BorgstromHenry Noppa OriginalPaper Pages: 133 - 137
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study H. T. MouridsenMichael CornbleetJohn Smyth OriginalPaper Pages: 139 - 148
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (A South West Oncology Group Study) John D. CowanC. Kent OsborneClarence B. Vaughn OriginalPaper Pages: 149 - 152
A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer Joseph C. AllegraT. WoodcockGary Dukart OriginalPaper Pages: 153 - 161
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer R. MetzM. DelgadoG. Mathe OriginalPaper Pages: 163 - 166
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer P. PeritiG. Robustelli Delia CunaE. Mini OriginalPaper Pages: 167 - 171
Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity Timothy J. PerrenGeorge BlackledgeA. Hancock OriginalPaper Pages: 173 - 177
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer John M. BennettPatrick ByrneGary Dukart OriginalPaper Pages: 179 - 185
Phase II studies of mitoxantrone in patients with primary liver cancer Geoffrey FalksonBarend Johannes Coetzer OriginalPaper Pages: 187 - 189
Mitoxantrone in refractory acute leukemia in children: A phase I study Kenneth A. StarlingArlynn Faye MulneGary Dukart OriginalPaper Pages: 191 - 195
A phase II study of mitoxantrone in acute leukemia Tohru MasaokaHirotoshi ShibataHiroya Kawagoe OriginalPaper Pages: 197 - 201
Mitoxantrone in the treatment of relapsed and refractory acute leukemia P. MeyerA. D. HoE. Seither OriginalPaper Pages: 203 - 206
Sequential studies on the role of mitoxantrone in the treatment of acute leukaemia H. G. PrenticeJ. Z. WimperisG. Robbins OriginalPaper Pages: 207 - 212
Phase I–II trial of mitoxantrone in acute leukemia: an interim report Zalmen A. ArlinGary DukartThe Lederle Cooperative Group OriginalPaper Pages: 213 - 217
Mitoxantrone in malignant lymphoma Richard A. GamsShelley BryanRichard Stein OriginalPaper Pages: 219 - 222